The goal of dry eye treatment is to somehow suppress both the elevated NGF levels and the dry eye symptomology in order to reduce the rises in inflammatory parameters (pro-inflammatory cytokine release), resulting from TRPV1 activation [67]. This evidence concerns the gene NGF and Keratoconjunctivitis sicca.